PDGFRB and acute myeloid leukemia: Recognizing AML with eosinophilia due to PDGFRA and PDGFRΒ rearrangement is important, because the aberrant tyrosine kinase activity can make the disease responsive to tyrosine kinase inhibitors such as imatinib.